Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
By P. Jänne, A. Shaw, J. R. Pereira, G. Jeannin, J. Vansteenkiste, C. Barrios, F. Franke, L. Grinsted, V. Zazulina, Paul D. Smith and 2 more. The Lancet Oncology, 2013
670 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/a81aa529b061a69fd9128338995582bab82b3be6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- The MAPK pathway across different malignancies: A new perspective (2014, background): “014).(56) Currently, many ongoing phase 2 clinical trials are exploring the use of agents targeting BRAF (Table 2) and MEK kinases (Table 3).”
- Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Selumetinib (AZD6244; ARRY-142866) a MEK1/MEK2 inhibitor showed a PFS advantage when combined with docetaxel in a recent phase II trial in advanced KRAS-mutant NSCLC (128).”
- Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities (2015, neutral): “Both efforts to directly target RAS oncoproteins with small molecules as well as alternative approaches focused on inhibiting RAS post-translational modifications or downstream signaling pathways have been employed with only limited success; recently, however, some promising results have been report”